Menu

S. Verstovsek

Articles

P.36 Phase 2, open-label, multicenter study to evaluate the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (FIGHT-203)

BJH - volume 11, issue Abstract Book BHS, february 2020

T. Devos MD, PhD, J. Gotlib , E. Asatiani , C. Walker , H. Zhen , S. Verstovsek

Read more
Top